Alumis Completes Merger with ACELYRIN
Deal News | May 21, 2025 | Globenewswire
Alumis Inc., a late-stage biopharmaceutical company, has announced the completion of its merger with ACELYRIN, Inc. As part of the merger, each ACELYRIN stockholder is to receive 0.4814 shares of Alumis common stock for every share of ACELYRIN common stock held. Following this merger, ACELYRIN's common stock has stopped trading on the NASDAQ Global Select Market. Alumis plans to leverage this merger to enhance its financial strength, aiming to extend its cash runway until 2027 while advancing its portfolio of targeted therapies for immune-mediated diseases. The merger expects to streamline operations and financial planning, with Morgan Stanley & Co. LLC serving as financial advisors for Alumis and Cooley LLP as legal counsel. ACELYRIN's advisors included Guggenheim Securities, LLC and Fenwick & West LLP, alongside Paul Hastings LLP for legal matters.
Sectors
- Biopharmaceuticals
Geography
- United States – The merger involves companies based in South San Francisco, California, reflecting significant activity in the US biopharmaceutical sector.
Industry
- Biopharmaceuticals – The industry involved in the development of drugs and therapies, particularly focusing on immune-mediated diseases as highlighted by Alumis' and ACELYRIN's activities.
Financials
- 0.4814 shares of Alumis for each ACELYRIN share – The exchange ratio for the merger where ACELYRIN stockholders receive Alumis shares.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Alumis Inc. | Bidding Company | Company | A late-stage biopharma company focusing on developing next-generation targeted therapies for immune-mediated diseases. |
| ACELYRIN, Inc. | Target Company | Company | A company merged into Alumis, which resulted in the cessation of its public trading. |
| Morgan Stanley & Co. LLC | Financial Advisor | Company | Served as the financial advisor to Alumis for the merger. |
| Cooley LLP | Legal Advisor | Company | Provided legal advice to Alumis during the merger. |
| Guggenheim Securities, LLC | Financial Advisor | Company | Served as the financial advisor to ACELYRIN for the merger. |
| Fenwick & West LLP | Legal Advisor | Company | One of the legal advisors to ACELYRIN during the merger. |
| Paul Hastings LLP | Legal Advisor | Company | Provided additional legal advice to ACELYRIN during the merger. |